Member Info for marik

Excellent point maccad499

...foolish people, and without understanding.

The virus doesn't need a vaccine to mutate. The chances of mutation increase as the numbers infected increase. The deadly Indian variant originated from an area with a small percentage of the population vaccinated.

Retireby40, please stop saying sensible things on this board it goes against the grain.

Here's one to cheer you all up:

Someone gave a masterclass on valuation earlier, by focusing on just the diagnostics division:

1) "emerging biopharmas can rate at 20+ P/E’s" and
2) "To support the current SP we need to be earning about £25m p/a".

On that basis. the Avacta daily LFT sales need to be:

<50,000 daily = current share price

I'm topping up first again.

On the bright side and you have some conviction in the stock, the good news is Avacta has a lot to offer. There is plenty already said on the subject, I'll copy and paste if I deem there is interest or people have forgotten.

The support levels were sitting at approx. 155 and the price has been moving towards that over the last 10 days, there was a high likelihood that it was going to fall today unless there was an RNS.

Scaffers, both those items are not new information, the press has been out in force since handc0ck left the building giving "leaked" information by Ministers.

Why don't you offer some analysis instead then, if you think others aren't providing any?

Sharebel, what justification do you want ?

I agree Epping, moaning on here is a pointless exercise, to think this board will massively impact the share price is laughable. Best thing in this scenario is to assess your own positions, if you're over exposed then it's time to realise that the exchange isn't a get rich quick scheme.

It was retracing back to these levels over the last 10 days. Positive news would push the price up, but that requires patience not mood swings on a day to day basis. It's a "short-medium" not "short" term. I'm sure you were aware of that anyway, in which case relax.

It's information that needs to be RNS'd ;-)

I've linked the clinical study in case you want to read the outcomes. I find the part regarding "invasive mechanical ventilatory support" interesting:

"Ivermectin had no significant effect on preventing hospitalization of patients with COVID-19. Patients who received ivermectin required invasive mechanical ventilatory support earlier in their treatment. No significant differences were observed in any of the other secondary outcomes."

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5

Looking good

It's just random statements by someone (probably related to the incompetent Indian Government), nothing to do with Avacta.

I have to agree with Myles on this, the Chemo market could expand and be dominated by Avacta due to the preCISION platform.

https://twitter.com/MylesMcNulty/status/1412060701175209987

Wise

Some interesting points.

This was a great RNS today, puts Avacta in a very different league:

Avacta 100%
Comp A: 50%
Comp B: 0%

"The AffiDX® SARS-CoV-2 antigen lateral flow test has been evaluated with a small number of patient samples confirmed to be Delta variant positive and, for a Ct<29, the test was shown to correctly identify all the positive cases. In this study, two other commercially available lateral flow tests were evaluated: One test detected half the positive cases and the other detected none."